| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.14 | 0.08 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.068 | 0.08 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.08 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.08 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.08 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.063 | 0.08 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.08 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.08 |